findmyKOL

Daniel Ontaneda, MD

Enriched profile

Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University · Cleveland Clinic

ORCIDNPI
Region🇺🇸 Cleveland, OH · Midwest · United StatesSpecialtyNeurologyFocusMultiple Sclerosis Research Studies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2020–2024

Daniel Ontaneda is Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University at Cleveland Clinic. OpenAlex indexes 308 publications with 6,295 citations (h-index 42); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

Daniel Ontaneda, M.D., is Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The public record shows 308 publications with 6,295 citations (h-index 42), centered on Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 10 companies, 1 NIH-funded awards (2020–2024).

  • Most recent indexed publication: 2026 · Neurology and therapy
  • Top research focus: Multiple Sclerosis Research Studies
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Sclerosis3 trials

Research focus

OpenAlex concept fingerprint
Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseasesAdvanced Neuroimaging Techniques and ApplicationsSystemic Sclerosis and Related Diseases

Drugs & molecules

across trials, industry payments and publications
Ocrevusgeneric · OcrelizumabClinical trialsIndustry payments8Publications1Avonexgeneric · Interferon beta-1aClinical trialsIndustry payments14PublicationsPlegridygeneric · Peginterferon beta-1aClinical trialsIndustry payments14Publications

Works with

trial sponsors and companies reporting payments
Biogen, Inc.Clinical trialsIndustry payments23Genzyme CorporationClinical trialsIndustry payments10Celgene CorporationClinical trialsIndustry payments7

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
308publications

Distinct works indexed by OpenAlex, matched via ORCID; 69 in PubMed.

6,295citations

Total citations across indexed works.

42h-index

Hirsch index (OpenAlex). i10-index 102.

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2020–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 1 Sept 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    50%
    gamma-Aminobutyric Acid-ergic Agonist50%
    Baclofen100%
    Part D<11 patients
  • Nervous system

    50%
    Potassium Channel Blocker50%
    Dalfampridine Er100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 1 Sept 2026

1 NIH research award on record, funded 20202024 per NIH RePORTER. The latest:

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 1 Sept 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/daniel-ontaneda-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/daniel-ontaneda-b89b6574

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Daniel-Ontaneda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    consultqd.clevelandclinic.org/tag/daniel-ontaneda

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →consultqd.clevelandclinic.org
  • Other

    my.clevelandclinic.org/podcasts/neuro-pathways/diagnostic-criteria-for-multiple-sclerosis

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org
  • Other

    neuronext.org/profile/daniel-ontaneda-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →neuronext.org
4 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    Pontificia Universidad Católica del Ecuador

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com
  • Ph.D.

    Case Western Reserve University

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Editorial & leadership roles

journal and society appointments
  • Program Committee

    ACTRIMS Forum 2026

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →forum.actrims.org
  • Member

    International Advisory Committee on Clinical Trials in MS -- co-author of the 2024 McDonald diagnostic criteria for multiple sclerosis

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →consultqd.clevelandclinic.org
  • Editor for Topical Reviews

    Multiple Sclerosis Journal

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →journals.sagepub.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.